Vella V - Search Results

1

p73 tumor-suppressor activity is impaired in human thyroid cancer.

Frasca F, Vella V, Aloisi A, Mandarino A, Mazzon E, Vigneri R, Vigneri P. Frasca F, et al. Among authors: vella v. Cancer Res. 2003 Sep 15;63(18):5829-37. Cancer Res. 2003. PMID: 14522906

2

Editorial: Early diagnoses and treatments of uncommon breast cancers.

De Francesco EM, Vella V. De Francesco EM, et al. Among authors: vella v. Front Endocrinol (Lausanne). 2022 Oct 18;13:1042226. doi: 10.3389/fendo.2022.1042226. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36329883 Free PMC article. No abstract available.

3

Editorial: A year in review: discussions in cancer endocrinology.

Almeida M, Sharifi-Rad J, Vella V. Almeida M, et al. Among authors: vella v. Front Endocrinol (Lausanne). 2023 Sep 20;14:1289156. doi: 10.3389/fendo.2023.1289156. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37800140 Free PMC article. No abstract available.

4

Insulin/IGF Axis and the Receptor for Advanced Glycation End Products: Role in Meta-inflammation and Potential in Cancer Therapy.

Vella V, Lappano R, Bonavita E, Maggiolini M, Clarke RB, Belfiore A, De Francesco EM. Vella V, et al. Endocr Rev. 2023 Jul 11;44(4):693-723. doi: 10.1210/endrev/bnad005. Endocr Rev. 2023. PMID: 36869790 Free PMC article. Review.

5

Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer.

Belfiore A, Pandini G, Vella V, Squatrito S, Vigneri R. Belfiore A, et al. Among authors: vella v. Biochimie. 1999 Apr;81(4):403-7. doi: 10.1016/s0300-9084(99)80088-1. Biochimie. 1999. PMID: 10401676

6

The IGF system in thyroid cancer: new concepts.

Vella V, Sciacca L, Pandini G, Mineo R, Squatrito S, Vigneri R, Belfiore A. Vella V, et al. Mol Pathol. 2001 Jun;54(3):121-4. doi: 10.1136/mp.54.3.121. Mol Pathol. 2001. PMID: 11376121 Free PMC article. Review.

7

Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor.

Frasca F, Vigneri P, Vella V, Vigneri R, Wang JY. Frasca F, et al. Among authors: vella v. Oncogene. 2001 Jun 28;20(29):3845-56. doi: 10.1038/sj.onc.1204531. Oncogene. 2001. PMID: 11439348

8

Immunostaining for Met/HGF receptor may be useful to identify malignancies in thyroid lesions classified suspicious at fine-needle aspiration biopsy.

Ippolito A, Vella V, La Rosa GL, Pellegriti G, Vigneri R, Belfiore A. Ippolito A, et al. Among authors: vella v. Thyroid. 2001 Aug;11(8):783-7. doi: 10.1089/10507250152484646. Thyroid. 2001. PMID: 11525273

9

A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer.

Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, Pezzino V, Belfiore A. Vella V, et al. J Clin Endocrinol Metab. 2002 Jan;87(1):245-54. doi: 10.1210/jcem.87.1.8142. J Clin Endocrinol Metab. 2002. PMID: 11788654

10

Exclusion of c-Abl from the nucleus restrains the p73 tumor suppression function.

Vella V, Zhu J, Frasca F, Li CY, Vigneri P, Vigneri R, Wang JY. Vella V, et al. J Biol Chem. 2003 Jul 4;278(27):25151-7. doi: 10.1074/jbc.M301962200. Epub 2003 Apr 25. J Biol Chem. 2003. PMID: 12716888 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

126 results

Search Page

Filters